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Abstract
Erythropoietin (EPO), recognized as a tissue protective agent, can trigger anti-inflammatory 
and anti-apoptotic processes to delimit injury and promote repair by the binding tissue-
protective receptor. However, only at a high dosage can EPO exert tissue protective effects, 
which simultaneously elicits some severe erythropoiesis-related side effects. Thus, the 
structural modification of EPO for the prevention of side effects is undoubtedly required. 
This chapter reviewed the development from EPO to its peptide derivatives with tissue pro-
tective efficacy. We also discussed are the therapeutic effects and limitations of each peptide, 
signaling pathways involved and the benefits for translation.
Keywords: erythropoietin, peptide, helix B peptide, cyclic helix B peptide, tissue 
protection
1. Introduction
Tissue injury refers to the histologic lesions and the subsequent functional insufficiencies of 
tissues and organs that are caused by multiple sources, such as ischemia followed by reperfu-
sion [1], trauma [2], autoimmune inflammation [3], oxidative stress [4], drugs and toxicants [5], 
etc. In histology, it is characterized by the infiltration of pro-inflammatory cells and cytokines 
and the cellular necrosis and apoptosis induced by damage-associated molecular patterns [6, 7]. 
Considering the high morbidity and mortality it has caused, the protection from tissue injury is 
a major concern in the basic and clinical medical academies worldwide. Erythropoietin (EPO), 
recognized as the erythropoietic hormone secreted in response to anemia, was reported to trig-
ger anti-inflammatory and anti-apoptotic processes to attenuate tissue injury and promote the 
repairing of injured tissues by binding to tissue protective erythropoietin receptor (EPOR)/β 
common receptor (βcR) heterodimer [8]. However, only at a high dosage can EPO exert tissue 
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protective effects, which simultaneously elicits some severe erythropoiesis-related side effects 
[9]. Thus, the structural modification of EPO for the prevention of side effects is undoubtedly 
required. This chapter reviewed the development from EPO to its peptide derivatives with tis-
sue protective efficacy. Also discussed are the therapeutic effects and limitations of each pep-
tide, signaling pathways involved and the benefits for translation.
2. Erythropoietin: more than erythropoiesis
EPO is a glycoprotein hormone, which is predominately produced and secreted by the adult 
kidney in response to anemia [10, 11]. After sensing the hypoxic signal in anemic conditions, 
the fibroblasts in the interstitial area of the renal cortex are activated to produce EPO [12, 
13]. EPO stimulates erythropoiesis through binding to its EPOR expressed on the surface 
of the red blood cell progenitors and precursors in bone marrow [14, 15]. In normal condi-
tions, the level of erythropoietin in the blood is quite low [10]. Under hypoxic stress, how-
ever, EPO production may be increased up to 1000-fold, reaching 10,000 mU/ml in the blood 
[13]. In structure, EPO consists of four long alpha-helixes (A, B, C, and D) running in an up- 
up-down-down direction, connected by two long cross-over loops (AB and CD) and one short 
loop (BC). Among the four helixes, only helix A, C, and helix D and the loop connecting helix 
A and B within the dimensional structure are essential for interacting with EPOR, while helix 
B faces away from the interior of the receptor in the tertiary structure [13, 16–18].
During the past decade, greater interest has been paid to the pleiotropic biologic actions of EPO 
beyond the stimulation of erythropoiesis, which include anti-apoptosis, anti-inflammation, 
neurogenesis, and angiogenesis, as well as their consequent tissue protection [8, 19–21]. An 
increasing body of studies demonstrated that EPO exerts a powerful tissue-protective effect on 
a variety of organs and can prevent cellular apoptosis from some sources, including reduced 
or absent oxygen tension, ischemia–reperfusion, toxicity and free radical exposure. Our study 
in a murine model of renal injury showed that EPO protected kidneys against injury through 
decreasing positive myeloperoxidase neutrophils and suppressing the expression of pro- 
inflammatory cytokines and chemokines by the inhibition of NF-kB signaling pathway [22]. In 
the study with isolated porcine renal allografts, it was demonstrated that EPO promoted inflam-
matory cell apoptosis, drove inflammatory and apoptotic cells into tubular lumens, thereby 
leading to inflammation clearance in the involved tissue and organs [23]. We also reported in 
our recent study that EPO could affect the dynamics of macrophages in the model of rhabdo-
myolysis-induced acute kidney injury. In this study, EPO was found to ameliorate kidney injury 
by reducing macrophages recruitment and promoting phenotype switch from M1 to M2 [24]. 
In vitro study, EPO was shown to directly suppress pro-inflammatory responses of M1 mac-
rophages and promote M2 marker expression [24]. These results refreshed our understanding 
about the immunoregulatory capacity of EPO.
The mechanisms involved in the tissue protective effect of EPO was not well illustrated until 
the specific receptor mediating tissue protection was revealed, which was recently defined as 
a heterodimer composed of EPOR and CD131 [25]. CD131 also forms the receptor complexes 
with α receptor subunits specific for GM-CSF, IL-3, and IL-5 and thus is named as β common 
receptor [25]. In aqueous media, helix B and parts of the AB and CD loops face the aqueous 
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medium but away from the erythropoietic binding sites, which indicates that helix B mediates 
tissue protective effect of EPO via binding with EPOR/βcR heterodimer [26]. Following the 
interaction of EPO with EPOR/βcR, the Akt involved signaling pathway is reported to play a 
vital role in mediating intracellular signal transduction. The activation of PI3K/Akt pathway 
by EPO maintains the mitochondrial membrane integrity, prevents cytochrome C from release 
and modulates the activity of caspase cascade during cellular apoptosis [27, 28]. The blockade 
of Akt phosphorylation abrogates the anti-apoptotic and anti-inflammatory effect after EPO 
administration [28, 29]. Moreover, the activation of Akt after EPO treatment is also reported 
to protect against genomic DNA degradation and membrane phosphatidylserine exposure 
[28, 30]. Several transcriptional modulators in the downstream pathways of Akt have also 
been shown to mediate the tissue-protection of EPO. For example, EPO could down-regulate 
the activity of forkhead transcription factor (FOXO3a) through inhibitory phosphorylation, 
which renders FOXO3a ineffective to activate the transcription of nuclear genes involved in 
apoptosis [31]. Other mechanisms include the inhibition of glycogen synthase kinase-3β [32], 
a serine-threonine kinase that plays a significant role in the induction of apoptosis of neurons, 
vascular smooth muscle cells and cardiomyocytes, and the up-regulation of the anti-apoptotic 
Bcl-2 family member Bcl-xL [33].
3. Helix B surface peptide: a specific tissue protective peptide 
without erythropoietic effect
The role of EPO in anti-inflammation and anti-apoptosis inspired us to investigate if EPO 
could also be served as a potential therapy for tissue injury caused by the exposure to drugs, 
chemicals, or physical ischemia. However, the tissue protective effect of EPO only occurs at 
the dosage that is well above normal, which may simultaneously elicit severe side-effects 
associated with its erythropoietic effects such as polycythemia and hypercoagulation in the 
circulation [9]. The demand of high dose to exert the tissue protective activities may be caused 
by the relatively low affinity of EPO to the tissue-protective EPOR/βcR dimer receptor relative 
to the erythropoietic (EPOR)
2
 homodimer [15, 20, 34]. Being enlightened by the finding that 
helix B plays a dominant role in mediating the tissue protective effect by binding with EPOR/
βcR receptor, Michael Brines et al. first synthesized the nonerythropoietic, tissue-protective 
peptides derived from the tertiary structure of erythropoietin which comprises the amino acid 
sequence corresponding to helix B as well as the three residues within the proximal portion of 
the BC loop. The design of the novel peptide aims to mimic the three-dimensional structure 
that interacts with EPOR/βcR receptor to reproduce the tissue-protective activities of the full 
molecule [26]. This 11-mer peptide derivative was named as helix B surface peptide (HBSP) 
[26]. Following studies demonstrated that HBSP is sufficient to activate tissue-protective path-
ways representative of the full molecule and protect from injury in a wide variety of tissues 
and organs but without causing erythropoietic effects.
3.1. In cardiovascular system
HBSP was demonstrated to exert tissue protective effects first in the cardiovascular system after 
it was designed. The designers of this peptide showed that HBSP protected cardiomyocytes 
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from TNF-α apoptosis in an Akt-dependent pathway both in vitro and in vivo [26, 35]. In this 
study, the levels of serum creatinine kinase activity and of cardiac expression of atrial natriuretic 
peptide, a marker of chronic heart failure, were down-regulated in animals treated with HBSP 
[26, 35]. Then, the anti-atherosclerotic effects HBSP were investigated in vitro and in vivo [36]. In 
vitro, HBSP inhibited C-reactive protein induced apoptosis in human umbilical vein endothe-
lial cells and THP-1 cells to a great extent [36]. In the hyperlipidemic spontaneous myocardial 
infarction model of rabbits, HBSP was shown to significantly suppress the progression of coro-
nary stenosis and myocardial ischemia caused by atherosclerotic lesions and inhibit coronary 
artery endothelial cell apoptosis through the activation of Akt pathway and the corresponding 
decreased the production of TNF-α as well as modified macrophage M1/M2 polarization [36]. 
Similarly, in the myocardial ischemia-reperfusion injury model of mice, HBSP administration 
before reperfusion significantly reduced the myocardial infarct size, decreased cardiomyocyte 
apoptosis, reduced the activities of superoxide dismutase and partially preserved heart func-
tion through the upregulation of Akt/GSK-3β/ERK and STAT-3 [37]. In an in vitro study per-
formed by using a rodent cardiomyocyte cell line subjected to hypoxia-reoxygenation injury, 
HBSP was reported to have protective effects by reducing cellular apoptosis, mitochondrial 
reactive oxygen production, ΔΨm collapse, and cytochrome C release from mitochondria to 
the cytosol. Furthermore, HBSP inhibited the activation of caspase 9 and caspase 3 as well as 
the alteration of Bcl-2 family proteins induced by hypoxia-reoxygenation [38]. Diabetes is also 
one of the major causes of myocardial lesions. Diabetic cardiomyopathy (DCM) is a ventricu-
lar dysfunction independent of coronary artery disease and hypertension, which is associated 
with inflammation, myocardial apoptosis and fibrosis [39–41]. In a study regarding the protec-
tion of HBSP on DCM, HBSP notably improved cardiac function, attenuated cardiac interstitial 
fibrosis, inhibited myocardial apoptosis, and ameliorated mitochondrial ultrastructure in mice 
with diabetic cardiomyopathy through an AMPK-dependent pathway [42]. HBSP promoted 
aortic endothelial cell repair under hypoxic conditions in a model of aortic endothelial injury, 
in which HBSP enhanced scratch closure by promoting cell migration and proliferation [43]. 
Furthermore, EPO protected bovine aortic endothelial cells from staurosporine-induced apop-
tosis under hypoxic conditions. Hypoxia was associated with a reduction in nitric oxide (NO) 
production. HBSP notably increased NO production, in a manner sensitive to NO synthase 
inhibition, under hypoxic conditions but not under normoxic conditions [43]. In summary, mul-
tiple studies proved the protective effect of HBSP on myocardial tissues and endothelial cells 
in the cardiovascular system following the injury caused by insufficient oxygen supply and 
implied that Akt pathway played a critical role in this process.
3.2. In nervous system
Another field of research in which the protection of HBSP was well investigated is in the ner-
vous system. In one study by Robertson et al., the effects of HBSP on early cerebral hemody-
namics and neurological outcome post-injury were investigated in a rat model of mild cortical 
impact injury followed hemorrhagic hypotension [44]. The results demonstrated that both 
EPO and HBSP treated groups improved recovery of cerebral blood flow in the injured brain 
following resuscitation, and showed more rapid recovery in the performance of functional 
neural tests. This study suggests that HBSP has neuroprotective effects similar to EPO in this 
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model of combined brain injury and hypotension [44]. They later reported that the treatment 
with HBSP resulted in significantly improved performance after the rats were suffered from 
mild traumatic brain injury (mTBI), which was associated with decreased infiltration of CD68-
positive inflammatory cells in the damaged brain tissue [45]. The results suggest that HBSP 
may improve cognitive function following mTBI [45]. Among the patients with neuritis, neu-
ropathic pain is a quite common symptom, which may be due to nerve inflammation. The 
neuropathic pain results from several overlapping pathways, which then merges into a mag-
nified pain status with symptoms such as allodynia and hyperalgesia [46, 47]. The study by 
Pulman KG et al., examined the effects of HBSP on pain behavior in the rat model of neuritis 
[48]. The results showed that treatment with HBSP prevented the development of mechani-
cal allodynia caused by neuritis but not affect heat hyperalgesia [48]. In another study, HBSP 
treatment could reduce allodynia coupled to the suppression of spinal microglia response in a 
dose-dependent manner, which may result from HBSP-induced suppression of inflammation 
in central nervous system [49]. In the study on the therapeutic effects of HBSP in experimental 
autoimmune encephalomyelitis (EAE), the administration of HBSP to EAE rats significantly 
reduced the severity and shortened the duration of injury, reduced the infiltration of pro-
inflammatory cells and suppressed expression of pro-inflammatory cytokines such as IL-1β, 
IL-17, TNF-α, IFN-γ. The expression of inducible NO synthase and transcription factor T-bet 
at mRNA level was also reduced in spinal cords following HBSP treatment [50]. In the in vitro 
study, HBSP inhibited antigen-specific and non-specific lymphocyte proliferation and pro-
moted the polarization of Th2 and regulatory T cells (Treg) while suppressed the polarization 
of Th1 and Th17 cells in EAE lymph nodes [50]. In summary, these studies regarding the role of 
HBSP in nervous system revealed that HBSP could also protect the nervous tissue from injury, 
which was associated with the alteration of the cytokine and cell milieu to limit inflammation 
in the damaged nervous tissue.
3.3. In obesity and diabetes related disorders
Several recent studies focused on the evaluation of the effects and potential mechanisms of 
HBSP in obesity modulation and diabetes-related disorders. One study was performed by 
using male C57BL/6 J mice fed with high-fat high-sucrose (HFHS) diet [51]. HFHS diet treated 
mice exhibited insulin resistance, hyperlipidemia, hepatic lipid accumulation and kidney dys-
function, which was related to the impaired insulin signal pathway and reduced membrane 
translocation of glucose transporter 4 [51]. However, treatment with HBSP ameliorated renal 
function, reduced hepatic lipid deposition, and normalized serum glucose and lipid profiles, 
which were associated with improved insulin sensitivity and glucose uptake in skeletal mus-
cle. The mechanism included that HBSP attenuated the HFHS-induced overproduction of IL-6 
and fibroblast growth factor-21, and enhanced mitochondrial biogenesis in skeletal muscle 
[51]. In another study regarding the effect of HBSP on obesity, HBSP was found to protect 
against obesity and insulin resistance by suppressing adipogenesis, adipokine expression as 
well as attenuating macrophage inflammatory activation in lipid tissue [52]. The retinopathy 
is one of the most common complications of diabetes and remains one of the leading causes of 
non-congenital blindness [53]. In the diabetic retina, vasodegenerative phase is accompanied 
by neuroglial abnormalities and eventual depletion of ganglion cells [54]. HBSP was shown to 
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significantly reduce microglial activation and protected against neuroglial and vascular degen-
eration but without exacerbating neovascularization in the retina [55]. These findings suggest 
that HBSP has therapeutic implications for metabolic disorders, such as obesity, diabetes, and 
diabetic retinopathy.
3.4. In kidney
Our research mainly discussed the tissue protection of HBSP on kidney injury. In 2013, we 
investigated effects of HBSP and the expression of EPOR/βcR heterodimer receptor in a 
murine renal ischemia-reperfusion (IR) injury model [56]. We found that HBSP could signifi-
cantly ameliorate renal dysfunction and tissue damage, reduced apoptotic cells in the kidney 
and inhibited the activation of caspase-9 and caspase-3 [56]. The expression of EPOR/βcR in 
the kidney was up-regulated following ischemia-reperfusion injury but was down-regulated 
by the treatment of HBSP [56]. Further investigation revealed that the PI3K-Akt pathway 
was dramatically activated by HBSP. The treatment of the PI3K inhibitor, Wortmannin, 
abolished improved renal function and histologic structure by HBSP [56]. This study sug-
gests that HBSP could protect the kidney from IR injury in a PI3K-Akt dependent pathway. 
Then, we also investigated the role of HBSP in IR and cyclosporine A (CsA) induced kidney 
injury since both of them are unavoidable after kidney transplantation and associated with 
allograft dysfunction [57]. We found that the level of creatinine and blood urea nitrogen was 
increased by CsA but decreased by HBSP. HBSP also significantly ameliorated tubuloin-
terstitial damage and interstitial fibrosis, which were gradually increased by IR and CsA 
[57]. In addition, apoptotic cells, infiltrated inflammatory cells, and active caspase-3 posi-
tive cells were greatly reduced by HBSP. It was demonstrated for the first time that HBSP 
effectively improved renal function and tissue damage caused by IR and/or CsA, which 
might be through reducing caspase-3 activation and synthesis, apoptosis, and inflamma-
tion [57]. Similar findings were also reported by Nimesh SA Patel’s and Willem G van Rijt’s 
groups that HBSP has renoprotective capacities by anti-inflammation and anti-apoptosis in 
the injured kidney tissue [58, 59].
3.5. In liver
Very recently, the protective effect of HBSP on acute liver injury was investigated in Wu’s 
study. In this study, the acute liver injury was induced by the administration of carbon tet-
rachloride (CCl4) [60]. HBSP was demonstrated to significantly decrease serum alanine ami-
notransferase, aspartate aminotransferase, lactate dehydrogenase, and pro-inflammatory 
cytokines in liver tissues after CCl4 injection. The infiltration of CD3, CD8, and CD68 posi-
tive cells and the expression of cleaved caspase-3 were also significantly decreased by HBSP 
treatment. The glutathione peroxidase activity and survival rate increased, while the total 
apoptotic rate was reduced in the HBSP-treated group. As to the mechanism, the authors 
reported that HBSP activated the PI3K/Akt/mTORC1 pathway [60]. Thus, HBSP showed con-
vincing protective effects on CCl4-induced acute liver injury by ameliorating inflammation 
and apoptosis [60].
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4. Thioether-cyclized helix B peptide: a cyclized peptide with 
increased instability and tissue protective potency
Despite the powerful tissue-protective function exhibited in various organs by inhibiting inflam-
mation and apoptosis, the property of poor permeability to biomembranes, unstable second-
ary structure, and short half-time restricts the application of HBSP in translation study [26]. 
Therefore, the structurally optimized transformation of HBSP is urgently required. It is acknowl-
edged that peptide cyclization could provide an efficient strategy to overcome these problems 
[61]. Provoked by this, we for the first time introduced the head-to-tail cyclization to the struc-
ture of HBSP to improve its stability, since the backbone of the peptide was constrained by the 
cyclization in which the linkages between main chains were formed by thioether [62]. This newly 
designed and synthesized peptide was named as thioether-cyclized helix B peptide (CHBP) [62].
4.1. Novel properties and mechanisms
In the following study, we demonstrate that CHBP is significantly stable in the human plasma 
and has a 2.5-fold longer half-life time than HBSP, suggesting that CHBP is highly resistant to 
proteolytic degradation both in vitro and in vivo [63]. We also found in our study that due to 
its stability, this long-acting peptide could ameliorate renal IR injury to a greater extent than 
HBSP, for only one dose of CHBP exerted persistent renal protective effect throughout the one 
week post IR injury [63]. Autophagy is demonstrated to play a renoprotective role in IR injury 
and is closely related to cellular apoptosis and inflammation in kidney tissue [64]. We also 
found that CHBP could induce autophagy in the injured kidney by increasing LC3-II/I ratio as 
well as upregulating beclin-1 [62]. Furthermore, our study depicted possible signaling path-
ways involved in CHBP-induced autophagy, which included the regulation of mammalian 
target of rapamycin (mTOR) pathway and the activation of AMPK pathway. The activation 
of AMPK by CHBP then phosphorylated and activated tuberous sclerosis 2 (TSC2), which 
connected with tuberous sclerosis 1(TSC1) to form a heterodimer to inhibit the activation of 
mammalian target of rapamycin complex 1 (mTORC1). Meanwhile, the mTORC2-Akt path-
way was activated by CHBP and autophagy was induced by the altered mTORC1/mTORC2 
equilibrium [62]. Also, CHBP was reported to upregulate Treg and downregulate helper T cell 
17 (Th17) after renal IR injury to restore the Treg/Th17 balance [62]. These findings revealed 
the mechanisms that are involved in the tissue protective function in CHBP but have not been 
reported in HBSP yet.
4.2. CHBP in organ preservation
During the transport of donated organs, any strategies that can effectively protect against IR 
injury during the cold storage (CS) and reperfusion stages would be very beneficial for pre-
venting the delayed graft function after kidney transplant surgery. Thus, we administrated 
CHBP in the preservation solution and autologous blood perfusate to examine its effect on 
the preservation of isolated donor kidney in the following study [65]. The results showed that 
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the administration of CHBP during cold preservation of kidneys as well as autologous blood 
could ameliorate IR injury after hemoperfusion, which was associated with increased renal 
blood supply and improved renal tubular structure and function [65].
4.3. CHBP and anti-allograft rejection
As the professional antigen-presenting cells, dendritic cells (DCs) play a triggering role in acute 
rejection (AR) after transplant surgery. Thus, we investigated the effects of CHBP on DCs in the 
kidney transplantation model from Lewis to Wistar rats [66]. The results showed that five succes-
sive doses of CHBP administration after kidney transplantation could significantly ameliorate 
AR with the association of lower histological injury, apoptosis, and CD4+ and CD8+ T-cell infil-
tration in renal allografts. CHBP also reduced the expression of IFN-γ and IL-1β but increased 
the expression of IL-4 and IL-10 in the serum of receipt. The number of mature DCs was signifi-
cantly decreased in renal allografts treated with CHBP [66]. Also, the incubation of DCs with 
CHBP in vitro led to a reduction in TNF-α, IFN-γ, IL-1β and IL-12 levels and an increase of 
IL-10 level at the protein level in the supernatant [66]. In the mechanism study, CHBP inhibited 
TLR activation-induced DC maturation by increasing SOCS1 expression through Jak-2/STAT3 
signaling [66]. Our study suggested that CHBP suppressed renal allograft AR by inhibiting the 
maturation of DCs via Jak-2/STAT3/SOCS1 signaling.
4.4. CHBP and protection of mesenchymal stem cells
Mesenchymal stem cell (MSC) is a pluripotent stem cell originating from the mesoderm and 
has the potential to differentiate into multiple types of cells and tissues [67, 68]. Thus, MSC 
has long been considered as an ideal cell-based therapy in the repairing of tissue injuries. After 
adoptive transferred in vivo, however, MSCs may confront a variety of undesirable factors 
that could decrease their viability and activity [69, 70]. Among them, nutrient starvation is the 
major obstacle for MSCs within injured tissues. In our study regarding the effect of CHBP on 
MSCs in vitro, we found that CHBP could significantly improve the cell viability and suppress 
apoptosis of MSCs in a dose-dependent manner [71]. Starvation resulted in the mitochondrial 
dysfunction, and the treatment of CHBP could alleviate mitochondrial dysfunction by dimin-
ishing the oxidative stress from ROS, restore mitochondrial membrane potential and maintain 
mitochondrial membrane integrity through the activation of Nrf2/Sirt3/FoxO3a pathway [71]. 
Moreover, MSCs pretreated with CHBP were more resistant to nutrient starvation [71]. This 
study suggests that CHBP has the e prospects for sustaining stem cell survival under nutrient-
deprived conditions and improving the therapeutic effect of MSC-based treatment.
5. Perspective and limitation for translation into clinic
The research about CHBP in our center also includes its effects on other kinds of injuries, for 
example, aristolochic acid-induced acute kidney injury [72]. The study on the role of CHBP in 
acute and chronic allograft rejection is in progress as well. Although our understanding about 
CHBP has significantly increased, there is still plenty of work to do to translate this protective 
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peptide into clinical practice. For example, the pharmacokinetics and pharmacodynamics of 
CHBP are not examined so far. The dosage form design of this new drug should be improved 
for oral administration or intravenous injection. The clinical trials are indispensable before it 
is finally applied for clinical use. In a further study, we plan to investigate the effects of CHBP 
in primate models of acute organ injury which could better represent the analogous disorders 
in the human being. We believe that this smaller but stronger peptide derivative of EPO could 
facilitate the treatment of acute tissue injury shortly.
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